longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden 0.5 hours per response...

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

(Print or Type Re	esponses)																
1. Name and Address of Reporting Person *- CATLIN AVERY W			2. Issuer Name and Ticker or Trading Symbol Corbus Pharmaceuticals Holdings, Inc. [CRBP]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner							
(Last) (First) (Middle) C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 500 RIVER RIDGE DRIVE			3. Date of Earliest Transaction (Month/Day/Year) 05/20/2020						_			itle below)	Othe	r (specify below)		
(Street) NORWOOD, MA 02062			4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing/Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person							
(City)	,	(State)	(Zip)	Table I - Non-Derivative Securities Acq				Acquir	tired, Disposed of, or Beneficially Owned								
1.Title of Securi (Instr. 3)	ty	I	2. Transaction Date Month/Day/Year	2A. Deen Execution any (Month/D	Date.	(Ins		v	(A) (curities Acquired proposed of r. 3, 4 and 5) (A) or cunt (D)	(D) O Tr		ollowin on(s)	curities Beneg Reported	j	Ownership Form:	Beneficial Ownership
			Table II -					a cur	rently	n are not rec valid OMB l of, or Benefic rtible securiti	control	l numb		nless the f	orm displa	rs	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	(Month/Day/Year)	3A. Deemed Execution Date,	4. 5.1 Transaction of Code Secar) (Instr. 8) Ac		5. Numb of Deriv Securities Acquired or Dispo	Number Derivative Expi curities (Mor equired (A) Disposed (D) sstr. 3, 4,		ate Exercisable and		7. Title and Amount of Underlying Securities (Instr. 3 and 4)				9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s	Ownershi Form of Derivativ Security: Direct (D or Indirect)	Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercis	sable	Expiration Date	Title	or N	Number		(Instr. 4)	(Instr. 4)	
Stock Option(right to buy) (1)	\$ 7.3	05/20/2020		A	4	10,500		<u>(1</u>	D	05/20/2030	Comr	14	0,500	\$ 0	40,500	D	
Reportin	g Owr	iers															

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
CATLIN AVERY W C/O CORBUS PHARMACEUTICALS HOLDINGS, INC 500 RIVER RIDGE DRIVE NORWOOD, MA 02062	X					

Signatures

/s/ Avery Catlin	05/22/2020
**Signature of Reporting Person	Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not re-	equired to respond unless the form displays a currently valid OMB number.